Challenges in Fabry Disease: the Combination of Two Individually Amenable <i>GLA</i> Variants May Be Nonamenable to Migalastat
R Fernandes(Algarve Biomedical Center), Ilídio de Jesus(Hospital de Faro EPE), Hugo Costa(Algarve Biomedical Center), Olga Azevedo(British Heart Foundation), Daniela Carvalho Silva(Algarve Biomedical Center), Nuno Marques(Hospital do Espírito Santo), Teresa Mota(Algarve Biomedical Center), Dina Bento(Algarve Biomedical Center), Miguel Espírito Santo(Algarve Biomedical Center)
Cited by 3
Related Papers
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|356
Assessing cognitive decline in the aging brain: lessons from rodent and human studies
|npj Aging|2023|170
Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis
|Journal of the American College of Cardiology|2020|104
Using ChatGPT in Software Requirements Engineering: A Comprehensive Review
|Future Internet|2024|94
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
|New England Journal of Medicine|2025|51